SCHEDULE: Vanguard Discloses 9.3% Stake in Rhythm Pharmaceuticals

The Vanguard Group has filed an amended Schedule 13G, revealing a 9.3% beneficial ownership in Rhythm Pharmaceuticals Inc.

Summary

• The Vanguard Group beneficially owns 6,210,916 shares of Rhythm Pharmaceuticals Inc. Common Stock.
• This represents 9.3% of the total class of securities.
• Vanguard holds shared voting power over 490,294 shares and shared dispositive power over all 6,210,916 shares.
• An internal realignment occurred on January 12, 2026, where The Vanguard Group, Inc. ceased performing portfolio management services or administering proxy voting.
• Certain subsidiaries or business divisions of Vanguard are expected to report beneficial ownership separately (on a disaggregated basis) following this realignment.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive disclosure, primarily due to the continued significant institutional ownership by The Vanguard Group, which can signal stability and long-term interest in Rhythm Pharmaceuticals. The internal realignment at Vanguard is an operational detail for the reporting entity and does not directly impact the issuer's sentiment.

Positives

• The Vanguard Group, a major institutional investor, maintains a significant 9.3% stake in Rhythm Pharmaceuticals, indicating continued institutional interest.
• The holding is stated to be in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

Negatives

• No specific negative points related to Rhythm Pharmaceuticals' performance or operations are disclosed in this ownership filing.

Risks

• No specific risks related to Rhythm Pharmaceuticals are detailed in this beneficial ownership filing.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that The Vanguard Group's continued significant stake in Rhythm Pharmaceuticals underscores the ongoing institutional confidence in the biotechnology sector, particularly for companies with specialized therapeutic areas. Large passive investment managers like Vanguard often hold substantial positions across various industries, reflecting broad market exposure rather than specific strategic plays, though the sheer size of the holding can still be a positive signal.

Stakeholder Impact

• Shareholders of Rhythm Pharmaceuticals Inc. are informed of a major institutional investor's significant stake, which can influence market perception and liquidity.
• Clients of The Vanguard Group, including investment companies and other managed accounts, have the right to receive dividends or proceeds from the sale of these securities.

Next Steps

• Certain subsidiaries or business divisions of The Vanguard Group, Inc. are anticipated to report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc. in reliance on SEC Release No. 34-39538.

Key Dates

Recommendation

This filing is a disclosure of beneficial ownership by a major institutional investor, The Vanguard Group, in Rhythm Pharmaceuticals. While a significant stake from a reputable firm like Vanguard can be seen as a positive signal of institutional confidence, the filing itself does not provide operational or financial performance data for Rhythm Pharmaceuticals that would warrant a 'buy' or 'sell' recommendation. It primarily confirms an existing, substantial holding and an internal organizational change at Vanguard. Therefore, a 'hold' recommendation is appropriate, as the filing does not present new information that fundamentally alters the investment thesis for Rhythm Pharmaceuticals, but rather confirms ongoing institutional interest.

Keywords

Rhythm Pharmaceuticals, Vanguard Group, Beneficial Ownership, Institutional Investor, Schedule 13G, Common Stock, Investment Adviser, SEC Filing